226 PUBLICATIONS AND CONFERENCE PRESENTATIONS PUBLICATIONS BASED ON STUDIES PRESENTED IN THIS THESIS • Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, Hemels MEW, Huisman MV, Kruip M, Faber LM, Wiersma NM, Buding WF, Fijnheer R, Adriaansen HJ, Roes KC, Hoes AW, Rutten FH, Geersing GJ. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAILAF Randomized Controlled Trial. Circulation. 2024;149(4):279-89. doi: 10.1161/ CIRCULATIONAHA.123.066485. • Joosten LPT, van Maanen R, van den Dries CJ, Rutten FH, Hoes AW, Granger CB, Hemels MEW, Geersing GJ, van Doorn S. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2023;10(1):e002197. doi: 10.1136/openhrt-2022-002197. • Joosten LPT, Offerhaus JA, van Smeden M, Linschoten M, Bleijendaal H, Tieleman R, Wilde AAM, Rutten FH, Geersing GJ, Remme CA. Sex- and age specific association of new-onset atrial fibrillation with in-hospital mortality in hospitalised COVID-19 patients. Int J Cardiol Heart Vasc. 2022;39:100970. doi: 10.1016/j.ijcha.2022.100970. • Joosten LPT, de Boer AR, van Eerde EJB, van Doorn S, Hoes AW, Bots ML, Rutten FH, Geersing GJ. Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in primary care. Neth Heart J. 2022;30(10):459-65. doi: https://doi. org/10.1007/s12471-022-01667-x. • Joosten LPT, van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, Hemels MEW, Huisman MV, Roes KC, van den Bor RM, Buding WF, Rutten FH, Geersing GJ. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9:e032488. doi: 10.1136/ bmjopen-2019-032488. • Joosten LPT, van Doorn S, Rutten FH, Geersing GJ. Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation. Ann Intern Med. 2019;170(11):816817. doi: 10.7326/L19-0129. ADDITIONAL PUBLICATIONS • Joosten LPT, van Doorn S, Hemels MEW, Huisman MV, Rutten FH, Geersing GJ. Cumarine of DOAC bij kwetsbare ouderen met atriumfibrilleren? Ned Tijdschr Geneeskd. 2024;168:D8026. [Dutch] • Joosten LPT. Vastzittende vishaak. In: Eekhof JAH, Bruggink SC, Kruis AL. Bonten TN, Petrus AHJ. Kleine Kwalen in de huisartsenpraktijk. Houten: Bohn Stafleu van Loghum; 2024. P. 881-886. [Dutch]
RkJQdWJsaXNoZXIy MTk4NDMw